Analytical Data
-
Gene name
CG beta 3
- Application
-
Alternative Names
CG-B; CGB3; hCGB; HCG; CGb5; CGb7; CGb8; Choriogonadotropin subunit beta
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P0DN86；P01233
-
Expression Region
Pro31~Gln165
-
Protein Length
Partial
-
Molecular Weight
18kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The research on CG beta 3 recombinant protein primarily focuses on its potential role in various biological and therapeutic applications. CG beta 3, or corticotropin-glycoprotein beta subunit 3, is a component of glycoprotein hormones, which are critical regulators of several physiological processes, including growth, metabolism, and reproductive functions. Understanding the structure and function of CG beta 3 is essential due to its involvement in the regulation of hormone secretion and signaling pathways. Recent studies have highlighted its significance in endocrine disorders and various cancers, suggesting that CG beta 3 could serve as a novel biomarker or therapeutic target. Recombinant technology allows for the production of this protein in a controlled environment, facilitating detailed investigations into its biological activity, interaction with other proteins, and potential therapeutic applications. By utilizing techniques such as gene cloning and expression in suitable host systems, researchers aim to elucidate the mechanisms by which CG beta 3 exerts its effects and to explore its potential role in drug development. This research not only enhances our understanding of glycoprotein hormones but also opens avenues for innovative treatments aimed at mitigating hormonal imbalances and associated diseases.
